Technology – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 15 Feb 2023 17:31:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Leafbuyer Technologies, Inc. Announces Record Results: 45% Increase in Quarterly Revenue and First Profitable Quarter as Public Company https://mjshareholders.com/leafbuyer-technologies-inc-announces-record-results-45-increase-in-quarterly-revenue-and-first-profitable-quarter-as-public-company/ Wed, 15 Feb 2023 17:31:53 +0000 https://cannabisfn.com/?p=2972627

Ryan Allway

February 15th, 2023

News, Top News


Financial Highlights:

  • Profitable: Net Income of $95,397 in Q2 from a Net Loss of $1,373,858 in the prior year
  • Revenue rose 45% from $923,829 to $1,341,750 in the second quarter of fiscal year 2022
  • Gross Profit increased 174% from $261,770 to $716,146 in the same period
  • Operating Expenses decreased 23% from $750,675 to $579,978

DENVER, CO / ACCESSWIRE / February 15, 2023 / Leafbuyer Technologies (OTCQB:LBUY) (“Leafbuyer” or “the Company”) a leading cannabis technology and marketing platform, announced today that quarterly revenue rose 45% year over year in the quarter ending December 31, 2022. The company also announced that it achieved profitability for the quarter. The financial data reflects the GAAP revenue booked in the quarter versus the same quarter of the previous year.

Kurt Rossner, Chief Executive Officer of Leafbuyer stated, “We achieved the best quarter in the Company’s existence, even though we streamlined costs and automated many systems. Our growth was significantly higher than the industry average and we are now one of the few publicly traded cannabis marketing firms, that is profitable.”

“Our goal is to continue this growth and increase earnings while we build industry leading products. We look to launch some significant updates and enhancements to our platform in 2023 as we continue to scale nationally,” Rossner added.

About Leafbuyer Technologies, Inc.

Leafbuyer Technologies is one of the most comprehensive marketing technology providers in the cannabis industry. Hundreds of cannabis businesses use the Leafbuyer texting and loyalty platform and the Custom App solution to engage with current and potential customers. Leafbuyer.com is a robust online resource for cannabis consumers, and the company’s partnerships with other websites have created a national network of cannabis deals and information that reaches millions of consumers every month.

Learn more at http://www.tech.leafbuyer.com/

Contact:

Leafbuyer Technologies, Inc.
Vida Almich 720.427.3927
vida@leafbuyertech.com

Cautionary Statement Regarding Forward-Looking Information Safe Harbor Statement

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in the forward-looking statements due to several factors detailed from time to time in our filings with the Securities and Exchange Commission. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings.

SOURCE: Leafbuyer Technologies, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Leafbuyer Announces Continued Strong Sales with a 33% increase in Quarterly Revenue https://mjshareholders.com/leafbuyer-announces-continued-strong-sales-with-a-33-increase-in-quarterly-revenue/ Tue, 15 Nov 2022 15:31:08 +0000 https://www.cannabisfn.com/?p=2968809

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

]]>
Bioharvest Sciences Inc. Successfully Completes Cannabis R&D Program https://mjshareholders.com/bioharvest-sciences-inc-successfully-completes-cannabis-rd-program/ Wed, 23 Mar 2022 13:45:41 +0000 https://www.cannabisfn.com/?p=2941572

Ryan Allway

March 23rd, 2022

News, Top News


  • Now producing Cannabis biomass in large scale industrial bioreactors under the current R&D license.
  • Commencing the process of transitioning the current Israeli Cannabis R&D license to a production license.

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – March 23, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) today announced that it has produced Cannabis Biomass in large scale industrial bioreactors, which represents the completion of the Company’s Cannabis R&D program.

On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. Building on that breakthrough, the Company has made significant progress, and has now produced Cannabis in large scale industrial bioreactors, marking the start of the transition to commercial scale manufacturing. To that end, the Company has commenced the process to obtain a production license in Israel for its Cannabis products to complement the R&D license it has used to date for the Cannabis development program.

Dr. Yochi Hagay, CTO, said “I am elated and proud of this achievement. The R&D team has relentlessly pursued this moment, which marks a new era for the Cannabis industry. Our proprietary and unique amalgamated trichome structure has proven resistant to shear forces applied during the cell growth process in liquid media and it will demonstrate more advantages when it comes to the medicinal application of our products. I have never doubted our ability to use our CELLicitation technology to produce Cannabis without the need to grow the plant itself and we have broken biological barriers to grow high performance trichomes in liquid suspension. We are now ready to bring our first unique Cannabis compositions to the world. We will of course continue to invest in Cannabis R&D to add more Cannabis products to the portfolio, appreciate the IP assets and drive even further manufacturing efficiencies.”

BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will support the scaling of successful sales of VINIA® in the US and beyond.

Ilan Sobel, CEO, states “Our unprecedented achievements present a great opportunity for the Cannabis industry. Consistent, clean, and efficacious Cannabis that is produced with the highest ESG credentials and capital efficiency with significantly lower manufacturing costs is the revolution this industry needs to gain further market traction and trust by the regulators worldwide. Our CELLicitation platform technology is a true market disruptor, cementing BioHarvest’s position as a leader in plant cellular biology. With the completion of the initial Cannabis R&D program, more focus can now be applied towards achieving the desired scale for our two business verticals, Polyphenols/Antioxidants and Cannabis.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: [email protected]

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company’s products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF https://mjshareholders.com/medipharm-labs-enters-united-states-pharmaceutical-market-with-submission-of-fda-dmf/ Wed, 23 Feb 2022 16:42:42 +0000 https://www.cannabisfn.com/?p=2938617

Ryan Allway

February 23rd, 2022

News, Top News


  • Completed a Drug Master File (“DMF”) process for CBD Active Pharmaceutical Ingredient (“API”) for the US Federal Drug Administration (“FDA”).
  • Use of Canadian Drug Establishment Licence (“DEL”) to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs.
  • The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025(i).
  • This is the only US FDA for CBD by a Canadian company and the second natural CBD DMF at commercial scale in all of North America(ii).

TORONTOFeb. 23, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice (“GMP”) CBD for development purposes to multiple established pharmaceutical companies.

Management Commentary

Bryan Howcroft, CEO, MediPharm, commented, “The filing of a US DMF further advances MediPharm toward its ultimate objective of becoming a dominant supplier of API to pharmaceutical companies. This is a high value, high margin opportunity, and with the only purpose-built facility in North America to receive a domestic GMP license specifically for the extraction of natural cannabinoids, MediPharm is positioned to capture share in this growing market. In the short to medium term, the DMF unlocks new sales channels and will enable us to further leverage the investments made to date on our high-quality pharmaceutical manufacturing platform. Over the longer-term, it ensures the Company is positioned as the go-to cannabinoid partner for pharmaceutical companies around the world.”

Additional Information

DMFs are regulatory submissions filed with the FDA containing confidential, detailed information about manufacturing, processes, packaging, and stability of APIs to be used in medicinal products for human use. Once the DMF filing is accepted by the FDA, pharmaceutical companies can reference the DMF when making a regulatory submission.

There are many large commercial opportunities for an API in new drug applications (“NDAs”) and abbreviated new drug applications (“ANDAs”). NDAs and ANDAs can be divided into the following four categories:

  1. A standalone NDA for new novel drugs.
  2. A 505(b)(2) application is a NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant.
  3. An ANDA for a previous approved drug creating a new generic drug.
  4. A petitioned ANDA is a type of ANDA for a drug product that differs from the novel drug in dosage form, route of administration, strength, or active ingredient.

About MediPharm Labs

Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

In 2021, MediPharm received a DEL from Health Canada, becoming the only company in North America to hold a domestic GMP License for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: acceptance of the DMF by the FDA and timing thereof; registering API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs; predictions regarding the cannabis-based drug opportunity; supplying approved API to pharmaceutical companies currently conducting late-stage research; becoming a dominant supplier of API to pharmaceutical companies; unlocking new sales channels; enabling the Company to further leverage the investments made to date on its high-quality pharmaceutical manufacturing platform; and positioning the Company as the go-to cannabinoid partner for pharmaceutical companies around the world. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

_________________________________

i Prohibition Partners

ii FDA 2021 Q4 report

SOURCE MediPharm Labs Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
The Cannifornian Podcast Explores The WeedTube https://mjshareholders.com/the-cannifornian-podcast-explores-the-weedtube/ Thu, 20 May 2021 04:45:37 +0000 https://www.thecannifornian.com/?p=20894 On today’s new episode of The Cannifornian Podcast, meet Ariana Newton, community manager of The WeedTube!

The post The Cannifornian Podcast Explores The WeedTube appeared first on The Cannifornian.

]]>

On today’s new episode of The Cannifornian Podcast, meet Ariana Newton, community manager of The WeedTube! We are super excited to have her on our podcast. Working for The WeedTube, she has a great perspective on cannabis marketing. Since she is also a content creator with her own account, she has wonderful insights about cannabis content trends as well.

Get into the conversation as Kevin and Betty Blazed discuss with Ariana how cannabis content creators struggle with platform regulations, how cannabis marketing is a struggle within itself and how The WeedTube has created a welcoming space for both!

Let’s get started!

Remember to listen to The Cannifornian Podcast on your favorite streaming platform and be sure to check us out on our  social media channels @thecannifornian, while enjoying our Weekly Dose Newsletter we send out every Tuesday!

Enjoy our latest podcast now!

The Podcast is available on any of these platforms.

The views expressed by guests on this podcast are their own and no endorsement is implied by their appearance. Views expressed by podcast employees are those of the employees and do not necessarily reflect the views of The Cannifornian, its parent company, or its affiliates.

]]>
How Social Media Censorship is killing the Marketplace https://mjshareholders.com/how-social-media-censorship-is-killing-the-marketplace/ Tue, 26 Jan 2021 00:45:10 +0000 https://www.thecannifornian.com/?p=20470 It has become clearer than ever that the long reaching arms of social media companies have the power to control the way we express ourselves to the public... Failure to comply with the terms of service can lead to a terrible fate...

The post How Social Media Censorship is killing the Marketplace appeared first on The Cannifornian.

]]>
How Social Media Censorship is killing the Marketplace – The Cannifornian




]]>
Why Focus on Cannabis & Mushroom Extracts? https://mjshareholders.com/why-focus-on-cannabis-mushroom-extracts/ Wed, 25 Nov 2020 14:25:14 +0000 https://www.cannabisfn.com/?p=2886586

Ryan Allway

November 25th, 2020

App, Exclusive, News, Top Story


Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion by 2024, which represents a respectable 8% compound annual growth rate.

Let’s take a look at the growing demand for cannabis and other extracts and why Pure Extracts Technologies Corp. (CSE: PULL) is well positioned to capitalize on the market.

Powering Next-Gen Products

Canada legalized cannabis extracts in October 2019, opening the door to edibles, beverages, topicals and vaping products. While dried cannabis still represents about 70% of sales, cannabis extracts and edibles have each captured about 14% of the market. Cannabis edibles, in particular, have become one of the fastest growing segments of the market.

Growth in Cannabis Edibles – Source: Canada Government

There’s no doubt that cannabis extracts, such as edibles and beverages, appeal to a wider consumer market than dried cannabis. On the other hand, the production of hash, rosin and other extract-based products has provided legal alternatives to popular black-market products – where much of sales remain outside of legal dispensaries.

Many large, licensed producers have begun scaling up their in-house extraction capabilities, but many others have outsourced extraction to specialists. With experienced teams and equipment, these companies offer better economies of scale by taking in raw cannabis and converting it into a variety of extract-based products for resale to consumers.

Recurring Revenue & Blue-Sky Potential

Pure Extracts Technologies Corp. (CSE: PULL) provides tolling and white-labeling services via its state-of-the-art 10,000 sq. ft. EU GMP-compliant cannabis and hemp extraction facility. After securing a processing license and agreements with Licensed Producers, the Company is already generating revenue through tolling agreements and will soon scale up its white label business.

Click here to receive and investor presentation and corporate updates

In addition, the Company has developed its own nationally recognized vape pen brand, called Pure Pulls, with over 34 proprietary formulations. The team is in the process of applying for a sales license to bring Pure Pulls back to market in the near-term, along with its edibles brand, Pure Chews, which could open the door to blue sky revenue potential.

The Company is also expanding its business to include mushroom extracts by working on functional mushroom extraction processes compatible with its existing infrastructure. Management believes that there exists a significant opportunity for it to become an important extraction partner for the commercialization of new functional mushroom products.

Exceptional Management Team

Pure Extracts Technologies (CSE: PULL) has assembled an impressive management team and advisory board. With a flat management structure, the team is laser-focused on creating high-quality products and building a sustainable business that’s EBITDA positive. These efforts could unlock significant long-term shareholder value in a growing market.

 CEO Ben Nikolaevsky joined the Company after serving as President and CEO of Natura Naturals Inc., a private Licensed Producer that was sold to Tilray Inc. (NASDAQ: TLRY). Founder and COO Doug Benville brings substantial experience with cannabis extracts, while Andy Gauvin brings a wealth of sales experience after serving as a vice president at Moosehead Breweries.

In addition to its management team, the Company recently appointed Dwight Duncan, a senior member of the Ontario Legislature, to its Board of Directors, as well as Dr. Alexander MacGregar, an expert in drug delivery technologies, to its Advisory Board. These appointments reflect its focus on regulatory compliance and research and development.

Click here to receive and investor presentation and corporate updates

The Bottom Line

Pure Extracts Technologies Inc. (CSE: PULL) recently secured a processing license from Health Canada and went public on the Canadian Securities Exchange. With an experienced and focused team at the helm, investors may want to take a look at the stock as a way to capitalize on the growing demand for cannabis and other plant-based extracts.

For more information, visit the Company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today https://mjshareholders.com/mydecine-innovations-group-announces-the-official-mindleap-health-mobile-app-launch-in-ios-and-android-stores-today/ Wed, 30 Sep 2020 17:43:53 +0000 https://www.cannabisfn.com/?p=2827904

Ryan Allway

September 30th, 2020

App, News, Top News


DENVER, Colorado, USA – September 30th, 2020 – Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:

Download on Android

Download on IOS  

Mindleap™ is designed to increase access to mental health services and provide analytics into mental health to improve outcomes starting with goal-setting, mood, emotion, and habit tracking. The platform is free to use for end users and for specialists who want to build a profile after passing the company’s approval process. It is only when an end user purchases services on the platform that Mindleap charges a 9% fee as a percentage of each session.

This is a unique approach that can allow anytime and anywhere access to vetted mental health professionals, and also allows specialists to get approved, set their prices, update their calendar and immediately begin treating new clients. Additionally, users on Mindleap can share their mental health data with their specialist during a secure HD video call to create a more data-driven conversation, as mental health can be very anecdotal and is often hard for people to explain. This convenient and innovative approach coupled with a unique focus on psychedelic integration provides value to both end users and specialists using the software.

The telehealth market is projected to become a $560 billion market by 2027, according to Fortune Business Insights™, which represents a 25.2% compound annual growth rate. The global pandemic has only increased high demand for telehealth services and it’s expected there will be over 1 billion telemedicine sessions by the end of 2020. Mindleap’s innovative technology and business model strive to capture a unique and growing piece of that market starting with psychedelic integration services and expanding into digital mental health programs and other types of mental health services.

Founder and CEO of Mindleap Health, Nikolai Vassev, commented, “It is incredible that a simple idea has become a vibrant company with innovative technology that will soon create a lot of happy customers. Our team carried out the development of an extremely complex system in a short period of time and we are just getting started. Our culture is about continuous improvement and we are already developing our advanced mental health analytics capabilities.”

About Mindleap Health

Mindleap is a telehealth solution that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every user. Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand.

Download for Android

Download for IOS

Watch the Mindleap Platform Overview Video

Apply to become a Specialist on Mindleap

Learn about Mindleap Health

Learn about The Past and Future of Psychedelics as a Medicine

About Mydecine Innovations Group

Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
[email protected]

Corp Communication:
Charles Lee, Investor Relations
[email protected]

Public Relations:
Cynthia Salarizadeh, Public Relations
[email protected]

Mindleap Health Platform Services Disclaimer: Mindleap Services are designed to connect users of our Services with mental health specialists so as to receive assistance and guidance with integrating their prior psychedelic or consciousness-expanding experiences and translating them into positive changes. Our Services are not designed or intended for the integration or translation of a presently occurring psychedelic experience and must not be used for that purpose. Psychedelic substances are legally controlled or prohibited in many jurisdictions, but there are legal means to have a psychedelic or conscious-expanding experience in certain circumstances. You are solely responsible and liable for adequately informing yourself of the Laws of your jurisdiction before using our Services and determining if use of our Services and the receipt of Specialist Services (defined below) is lawful in your jurisdiction. Our Services are meant to be used exclusively in connection with lawful activities and must not be used in connection with illegal substances or illegal activities. Without limiting the previous sentence, you are not permitted to promote, procure, consume, or sell illegal substances through the Services. Do not use psychedelic substances if doing so is unlawful in your jurisdiction. Possession of psychedelic substances in violation of applicable laws can carry significant penalties, including years of incarceration.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
What Are Functional Mushrooms? https://mjshareholders.com/what-are-functional-mushrooms/ Mon, 17 Aug 2020 12:47:45 +0000 https://www.cannabisfn.com/?p=2806769

Ryan Allway

August 17th, 2020

App, Exclusive, Psychedelics, Top Story


Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, and fiber.

As with cannabis and other plant-based medicines, the beneficial properties of functional mushrooms can be extracted into a wide range of formats. These formats provide patients and consumers with different product options, improved bioavailability and greater consistency, which opens the door to a range of medical and consumer use possibilities.

Let’s take a closer look at functional mushrooms, how extraction plays a role in product development and how Pure Extracts Inc. (CSE: PULL) (listing pending) plans to capitalize on the space.

Functional mushrooms provide a wide range of potential health benefits that researchers are only starting to understand. While some have become popular superfoods, others are an important source of vitamins for supplements.

Some popular functional mushrooms include:

  • Reishi:  a Traditional Chinese Medicine ingredient that supports restful and healthy sleep, reduces stress and boosts the immune system.
  • Chaga: rich in antioxidants that could help strengthen the immune system—it was even used as a coffee ration in World War II.
  • Shiitake: a widely known superfood with nine amino acids and a diverse range of important vitamins and minerals.
  • Oyster mushrooms: contain beta-glucans that could improve cholesterol and blood sugar markers, as well as boost the immune system.
  • Trumella: a common source for plant-based vitamin D as it contains more of the vitamin than any other known food source.

Psilocybin has become one of the most popular mushrooms following the movement to legalize psychedelics across several states and some countries. Over the past couple of years, researchers found that the mushroom’s psychedelic properties could have wide ranging implications across psychology and psychiatry practices targeting mental illnesses.

Click here to learn more about investing in mushroom extraction technology

Many of the world’s most popular medicines originated from plants—specifically, plants in the Amazon rainforests. Of course, modern medicine doesn’t typically involve consuming or smoking exotic plants—with the exception of medicinal cannabis use. The beneficial properties are extracted into safe and consistent formats that physicians can prescribe.

Vitalis Extraction Technology – Source: Vitaliset

The same is true for over-the-counter supplements that extract beneficial properties from plants and other sources and combine them into a more palatable format. While supplements aren’t subject to as much regulation, extraction can help them meet FDA guidelines for safe production and an improved shelf life compared to the original formats.

There are many different extraction methods used depending on the plant or input source, but CO2 extraction has become one of the most effective modern methods. When pressure is applied to CO2, the gas turns into a liquid that can be used as a very inert, safe, liquid solvent to extract oils from plant biomass, such as mushrooms, hemp and cannabis.

Click here to learn more about investing in mushroom extraction technology

Functional mushrooms are experiencing a renaissance fueled by interest in psilocybin for the treatment of mental health disorders. While there are a growing number of cultivators, investors may want to take a closer look at the extractors that are focused on functional mushrooms as potential opportunities given their innovative business models.

Pure Extract Technologies Inc. – which plans on going public on the Canadian Securities Exchange (CSE) in Q3 of this year using the symbol “PULL” – has built an EU-GMP compliant extraction facility in British Columbia with an initial focus on extracting cannabis and long-term plans to extract mushrooms. Extracts in both categories are expected to see tremendous growth over the coming years.

The business model is compelling for investors. After signing agreements with Licensed Producers, the Company either charges a toll for extraction services or produces white-label products on behalf of other companies, creating very little overhead and predictable, recurring revenue with attractive margins.

While the Company’s initial business will come from tolling and white labeling, Pure Extracts anticipates creating in-house brands that will benefit from the ready supply of biomass from Licensed Producers and its in-house extraction (i.e., at a lower cost). These dynamics could create an attractive business line in the future.

Functional mushrooms are quickly becoming a preferred health food and potential source of treatment options for mental health disorders. While there are a growing number of companies focused in the space, investors may want to take a look at extraction providers, such as Pure Extract Technologies Inc. (CSE: PULL), given its strong business model and unique focus.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
CBD Buyer’s Guide: Distillation https://mjshareholders.com/cbd-buyers-guide-distillation/ Fri, 05 Jun 2020 10:44:48 +0000 https://www.thecannifornian.com/?p=18402 We wanted to quickly cover some of the most commonly used CBD distillation processes in order to provide you with a more comprehensive understanding of what goes into the manufacturing of CBD products.

The post CBD Buyer’s Guide: Distillation appeared first on The Cannifornian.

]]>

The distillation process that CBD undergoes in order to obtain CBD isolate is often up to a manufacturer’s preferences, and there is not a lot of evidence that one distillation process is necessarily better than other commonly used distillation processes. Due to this, not many manufacturers even disclose what distillation process(es) that they use in the creation of their CBD isolate and their manufacturing of CBD products that use CBD isolate, but we will still quickly cover some of the most commonly used CBD distillation processes in order to provide you with a more comprehensive understanding of what goes into the manufacturing of CBD products:

  • Winterization: This is the process to remove undesirable elements that were extracted from the plant; some examples include: fats, natural waxes, and lipids. This process is only needed when the oil was extracted at high pressure and at a high temperature (which is known as supercritical extraction) because this intense extraction pulls everything from the plant, including — most importantly — material(s) that you don’t want in the final product. Once extracted, the mixture is combined with 200% proof alcohol and is then stirred vigorously until it is completely mixed. It’s then placed in a deep freezer for a period of at least 24 hours. After this freezing period, the mixture will have a cloudy look to it, and it is ready for the filtration process;
  • Short Path Distillation: This technique is often used for compounds which are unstable at high temperatures or in order to purify small amounts of the desired compound. The advantage of this distillation process is that the heating temperature of the product can be considerably lower (at reduced pressure) than the boiling point of the liquid or oil at standard pressure, and the distillate only has to travel a very short distance before condensing;
  • Fractional Distillation: This is the separation of a mixture into its different component parts, which are known as fractions. Chemical compounds are separated by heating them to a temperature at which one — or more fraction — of the mixture will vaporize. It uses distillation to fractionate, which is a separation process in which a certain quantity of a mixture (either gas, solid, liquid, enzymes, suspension, or an isotope mixture; in this case of CBD isolates it is the solid plant parts) is divided, into a group of smaller overall quantities;
  • Continuous Wipe Film Distillation: This is an ongoing separation in which a mixture is continuously fed into the process without any interruptions and separated fractions are removed continuously as outputs, removing them from the desired end product;
  • Batch Distillation: The use of distillation in groups or batches, meaning that a mixture is distilled to separate it into its component fractions before the distillation still is again charged with more mixture and the process is repeated. This is in direct contrast to continuous distillation described above;
  • Vacuum Distillation: This is a method of distillation performed under reduced pressure, which lowers the boiling point of most liquids. This technique is most commonly used when the boiling point of the desired compound (the CBD isolate) is difficult to achieve or will cause the compound to decompose or degrade, or even simply to save energy in heating.

See more of the CBD Buyer’s Guide
http://credit-n.ru/zaymyi-next.html

]]>